Show simple item record

dc.contributor.authorGullick, Nicola
dc.contributor.authorGullick, Nicola
dc.date.accessioned2024-05-29T12:34:22Z
dc.date.available2024-05-29T12:34:22Z
dc.date.issued2022
dc.identifier.citationGaffney K, Kiltz U, Sfikakis P, Gullick N, et al. Impact immediate treatment interruption of secukinumab efficacy in patients with active psoriatic arthritis and ankylosing spondylitis: interim analysis results from the SERENA study. Rheumatology 61(s1) April 2022en_US
dc.identifier.urihttp://hdl.handle.net/20.500.14200/4680
dc.description.abstractNot availableen_US
dc.language.isoenen_US
dc.publisherRheumatologyen_US
dc.publisherRheumatologyen_US
dc.titleImpact immediate treatment interruption of secukinumab efficacy in patients with active psoriatic arthritis and ankylosing spondylitis: interim analysis results from the SERENA studyen_US
dc.typeArticleen_US
rioxxterms.versionAOen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.affiliation11. Gaffney K, Kiltz U, Sfikakis P, Gullick Nen_US
dc.date.accepted2022
oa.grant.openaccessyesen_US


This item appears in the following Collection(s)

Show simple item record